Clinical Trial Update: Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of gemtuzumab ozogamicin in acute myeloid leukemia has completed, with Pfizer-Wyeth as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (Mylotarg) (gemtuzumab ozogamicin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED